In yesterday’s Wall Street session, Alto Neuroscience Inc. (NYSE:ANRO) shares traded at $4.13, down -5.28% from the previous session.
ANRO stock price is now -65.73% away from the 50-day moving average and -68.63% away from the 200-day moving average. The market capitalization of the company currently stands at $111.34M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $29 to $4, Wedbush Downgraded its rating from Outperform to Neutral for Alto Neuroscience Inc. (NYSE: ANRO). , while ‘Wedbush’ rates the stock as ‘Outperform’
In other news, Savitz Adam, CHIEF MEDICAL OFFICER bought 12,069 shares of the company’s stock on Jul 09 ’24. The stock was bought for $152,085 at an average price of $12.60. Upon completion of the transaction, the CHIEF MEDICAL OFFICER now directly owns 36,920 shares in the company, valued at $0.15 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 10 ’24, CHIEF MEDICAL OFFICER Savitz Adam bought 2,931 shares of the business’s stock. A total of $38,748 was incurred on buying the stock at an average price of $13.22. This leaves the insider owning 39,851 shares of the company worth $0.16 million. A total of 17.74% of the company’s stock is owned by insiders.
During the past 12 months, Alto Neuroscience Inc. has had a low of $4.26 and a high of $24.00. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 19.85, and a quick ratio of 19.85. The fifty day moving average price for ANRO is $12.0498 and a two-hundred day moving average price translates $13.167283 for the stock.
The latest earnings results from Alto Neuroscience Inc. (NYSE: ANRO) was released for 2024-06-30. The company reported revenue of $18.34 million for the quarter, compared to $7.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 154.7 percent.
